← All Checkpoint Therapeutics, INC filings

Checkpoint Therapeutics, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

CKPT
Checkpoint Therapeutics, INC
10-Q: Checkpoint Therapeutics Reports Q1 2025 Results, Merger with Sun Pharma Progresses
Checkpoint Therapeutics reports its Q1 2025 financial results and provides an update on its pending merger with Sun Pharmaceutical Industries.
CKPT
Checkpoint Therapeutics, INC
10-Q: Checkpoint Therapeutics Reports Q3 2024 Results, Faces Going Concern Uncertainty
Checkpoint Therapeutics reported its Q3 2024 financial results, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern.
CKPT
Checkpoint Therapeutics, INC
10-Q: Checkpoint Therapeutics Reports Q2 2024 Results, BLA Resubmission Accepted by FDA
Checkpoint Therapeutics announced its Q2 2024 financial results and the FDA's acceptance of its resubmitted Biologics License Application (BLA) for cosibelimab.
CKPT
Checkpoint Therapeutics, INC
10-Q: Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Corporate Update
Checkpoint Therapeutics' first quarter results reflect ongoing losses and reliance on future financing to continue development of its cancer treatment candidates.